Follow

ZINZINO AB (PUBL): PRELIMINARY SALES REPORT NOVEMBER 2021

03 December 2021 - 12:00

Strong sales growth during November; Zinzino group revenue increased with a total of 48%, compared with the previous year.

The revenue in November for Zinzino’s sales markets increased by 49% to SEK 140.7 (94.6) million due to strong growth in several regions. Faun Pharma’s external sales increased by 28% and amounted to SEK 5.5 (4.3) million. Overall, the Group increased revenues by 48% to SEK 146.2 (98.9) million compared with the previous year.

Accumulated revenue for January – November 2021 increased by 22% to SEK 1221.5 (1004.8) million.

Revenues were distributed as follows:

Regions,MSEK 21-Nov 20-Nov Change YTD 2021 YTD 2020 Change
The Nordics 32.0 35.9 -11% 333.7 356.1 -6%
Central Europe 25.2 15.5 63% 205.5 158.4 30%
East Europe 41.3 19.0 117% 304.9 232.5 31%
South & West Europe 15.5 9.3 67% 130.3 76.3 71%
The Baltics 10.3 7.2 43% 68.8 62.2 11%
North America 4.8 3.4 41% 45.3 37.1 22%
Asia-Pacific 11.0 4.3 156% 75.2 28.7 162%
Africa 0.6 0.0 0.6 0.0
Zinzino 140.7 94.6 49% 1164.3 951.3 22%
Faun Pharma 5.5 4.3 28% 57.2 53.5 7%
Zinzino Group 146.2 98.9 48% 1221.5 1004.8 22%

Countries in regions:

-The Nordics: Denmark, Faroe Island, Finland, Iceland, Norway, Sweden

-Central Europe: Austria, Germany, Switzerland

-East Europe: Czech Republic, Slovakia, Hungary, Poland, Romania

-South & West Europe: Cyprus, France, Greece, Italy, Netherlands, Spain, United Kingdom

-The Baltics: Estonia, Latvia, Lithuania

-North America: Canada, USA

-Asia-Pacific: Australia, Hong Kong, India, Malaysia, Singapore, Taiwan, Thailand

-Africa: South Africa

For more information:

Dag Bergheim Pettersen CEO Zinzino +47 (0) 932 25 700, zinzino.com

Pictures for publication free of charge:

Marcus Tollbom +46 (0) 70 190 03 12, [email protected]

Certified Adviser: Erik Penser Bank Aktiebolag, +46 (0) 8 463 83 00, email: [email protected]

Zinzino AB (publ) is obliged to publish this information in compliance with current EU regulations governing market abuse. The information was provided by the above contact person for publication at 12:00 the 3rd of December 2021.

Zinzino is a global D2C company from Scandinavia specializing in biomarker-based, personalized nutrition. It is a public limited company with its shares listed on Nasdaq First North Premier Growth Market. Their test-based, scientifically proven nutritional supplements are available in over 100 markets across the world.

Zinzino owns the Norwegian research and production units BioActive Foods AS and Faun Pharma AS. The company headquarters is in Gothenburg, Sweden with additional offices in Finland, Latvia, Norway, USA, Australia, Hong Kong, Malaysia, India,Taiwan and South Africa.

Provided by: Cision
Nasdaq First North GM (Sweden)
Zinzino Holding AB
Zinzino is a direct sales company which offers products focusing on nutritional supplements, skincare, and lifestyle products. The Company operates in three segments Zinzino; Faun and VMA Life....
Learn more about company
Media

Related news

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More